XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.33

-1.9%

Dec 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (15877)	7/14/2002 11:53:58 PM
From: aknahow	Read Replies (2) of 17367

I fully understand that contingencies exist for Xanelim as they do for any prospective drug. You are the one that does not get it. Kellogg just said getting final approval of Amevive is BGEN's largest challenge. He knows the contingencies but holders like you think approval is assured. You ignore the example of FluMist which just was subject to a new second, complete response letter. The Amevive presented to the world in the months prior to the FDA committee meeting is not the same Amevive that the FDA saw. The committee liked it but the FDA wondered both about efficacy and duration. Is this fact or fiction?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next